RMTI Rockwell Medical, Inc. - Common Stock
$7.58
Price · Aug 19, 2026
Fundamentals as of Aug 13, 2026
52W Range
$1–$8
95% of range
Analyst Rating
BUY
8 analysts
Price Target
$30
+296% upside
P/E (TTM)
-5.1
ROE
-15.8%
Net Profit Margin
-7.7%
About Rockwell Medical, Inc. - Common Stock Company overview from Wikipedia
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Read more
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
The company's primary customers are dialysis providers.
Products
Triferic
Triferic was approved by the Food and Drug Administration (FDA) in January 2015. Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Triferic replaces the iron lost during hemodialysis treatments. Triferic delivers iron directly to transferrin which transports it to the bone marrow to make hemoglobin. Rockwell is actively marketing and commercializing Triferic in the U.S. hemodialysis market. In February 2014, the Company completed its long-term safety study for Triferic.
Rockwell Medical began commercializing Triferic (dialysate) and Triferic AVNU (intravenous) in the United States in the second half of 2019 and in early 2021, respectively. Triferic was launched into a very competitive marketplace with well-entrenched products and a lack of consensus regarding unmet medical needs for dialysis patients with anemia. Due to its limited market adoption, unfavorable reimbursement, and absence of interest from other companies to license or acquire Triferic despite Rockwell's significant effort to partner the program, Rockwell Medical discontinued its New Drug Applications (“NDAs”) for Triferic and Triferic AVNU in the United States in the fourth quarter of 2022.
Calcitriol
Calcitriol (active vitamin D) generic is FDA approved for treating secondary hyperparathyroidism or hypocalcemia in hemodialysis patients.
Hemodialysis Concentrates
Rockwell is a manufacturer of hemodialysis concentrates/dialysates for dialysis providers and distributors in the U.S. and globally. Hemodialysis concentrates remove toxins and replace critical nutrients in the dialysis patient's bloodstream during hemodialysis. Rockwell has three U.S. manufacturing and distribution facilities.
Iron (III) pyrophosphate
One of the main treatments that the company develops is iron (III) pyrophosphate, for iron supplementation, a key element in the formation of new red blood cells. It was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis since the process accounts for treatment in around 90% of anemia patients.
International Partnerships
While Rockwell has discontinued commercialization of Triferic in the United States, the company has established international partnerships with companies seeking to develop and commercialize Triferic outside the United States and is working closely with these international partners to develop and commercialize Triferic in their respective regions.
South Korea for example; Triferic and Triferic AVNU have been approved in South Korea, and our partner, Jeil Pharmaceutical, launched Triferic in South Korea during the third quarter of 2022.
Also, in April 2023, Drogsan submitted a Marketing Authorization application and GMP application for Triferic AVNU to the Turkish Medicines and Medical Devices Agency ("TMMDA"), for which Drogsan received priority status and high priority status, respectively. Taking into consideration that Drogsan was granted an accelerated review for Triferic AVNU with the Turkish regulatory authority, Rockwell anticipates approval for Triferic AVNU in Turkey in 2024. Drogsan is responsible for all regulatory approval and commercialization activities.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
RMTI Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$7.58
Market Cap
$30M
P/E (TTM)
-5.1
EPS (TTM)
$-0.15
Revenue (TTM)
$69M
Div Yield
—
ROE
-15.8%
Debt/Equity
0.2
52W Range
$1 – $8
RMTI Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
$69M
2016-12-31
→
2025-12-31
EPS
$-0.15
2016-12-31
→
2025-12-31
Free Cash Flow
$-1M
2024-12-31
→
2025-12-31
Margins
-7.7%
2016-12-31
→
2025-12-31
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
RMTI
Peer Median
P/E (TTM)
-5.1
15.4
P/S (TTM)
0.4
2.8
P/B
0.8
1.6
EV / EBITDA
-11.2
—
Price / FCF
-24.9
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
RMTI
Peer Median
Gross Margin
16.9%
31.6%
Operating Margin
-6.8%
—
Net Profit Margin
-7.7%
-49.3%
ROA
-9.1%
-54.9%
ROE
-15.8%
-98.0%
ROIC
-10.2%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
RMTI
Peer Median
Debt / Equity
0.2
0.0
Current Ratio
4.0
4.7
Quick Ratio
2.0
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
RMTI
Peer Median
Revenue YoY
-31.8%
—
Revenue CAGR 3Y
-1.7%
—
Revenue CAGR 5Y
2.2%
—
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
RMTI
Peer Median
RMTI Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
8 analysts
- Strong Buy 2 25.0%
- Buy 5 62.5%
- Hold 1 12.5%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
2 analysts · 2026-08-15
Median
$30.00
← Below all targets
$7.58
Low
$20.00
High
$40.00
Median target
$30.00
+295.8%
Mean target
$30.00
+295.8%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.09%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.34 | $-0.24 | -0.10% |
| March 31, 2026 | $-0.40 | $-0.26 | -0.14% |
| Dec. 31, 2025 | $-0.10 | $0.20 | -0.30% |
| Sept. 30, 2025 | $-0.50 | $-0.46 | -0.04% |
| June 30, 2025 | $-0.50 | $-0.51 | 0.01% |
| March 31, 2025 | $-0.04 | $-0.05 | 0.01% |
| Dec. 31, 2024 | $-0.02 | $0.02 | -0.04% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| RMTI | $33M | -5.5 | -31.8% | -7.7% | -15.8% | 16.9% |
| UTMD | $178M | 16.1 | -5.8% | 29.3% | 9.5% | 57.1% |
| NSPR | $77M | -2.3 | 28.1% | -543.3% | -129.3% | 29.5% |
| TELA | $53M | -1.4 | 15.8% | -48.4% | -501.1% | 67.7% |
| ADVB | $15M | -4.4 | — | — | -159.1% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 17
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Cost of Revenue | $58M | $84M | $75M | $69M | $64M | $59M | $58M | $65M | $54M | $47M | $46M | $46M | |
| Gross Profit | $12M | $17M | $9M | $4M | $-2M | $3M | $3M | $-2M | $4M | $7M | $9M | $9M | |
| R&D Expense | $0 | $19.0K | $1M | · | · | · | · | $6M | $6M | $6M | $5M | $8M | |
| SG&A Expense | $14M | $14M | $12M | $16M | $15M | $16M | $21M | $22M | $23M | $21M | $19M | $18M | |
| Operating Income | $-5M | $608.0K | $-7M | $-17M | $-30M | $-28M | $-35M | $-32M | $-26M | $-20M | $-15M | $-18M | |
| Interest Expense | · | · | $2M | $2M | $2M | $2M | $25.0K | · | · | · | · | · | |
| Interest Income | · | · | $211.0K | $33.0K | $22.0K | $238.0K | $392.0K | · | · | · | · | · | |
| Other Non-op | $-623.0K | $-1M | $-2M | $-2M | $-2M | $-2M | $397.0K | $313.3K | $1.6K | · | · | · | |
| Pretax Income | $-5M | $-480.0K | $-8M | · | · | · | · | · | $-26M | $-19M | $-14M | $-21M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $404.5K | $0 | $0 | |
| Net Income | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| EPS (Basic) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| EPS (Diluted) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| Shares (Basic) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| Shares (Diluted) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| EBITDA | $-2M | $3M | $-5M | $-16M | $-30M | $-28M | $-34M | $-32M | $-25M | $-19M | $-14M | $-17M |
Balance Sheet 29
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $16M | $9M | $10M | $13M | $49M | $12M | $23M | $8M | $17M | $31M | $66M | |
| Short-term Investments | · | · | · | · | · | · | · | $11M | $25M | $41M | $39M | $20M | |
| Receivables | $8M | $8M | $11M | $6M | $6M | $4M | $4M | $7M | $6M | $6M | $5M | $4M | |
| Inventory | $3M | $6M | $6M | $6M | $4M | $4M | $4M | $4M | $8M | $12M | $8M | $4M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $3M | $3M | $3M | $2M | $2M | · | · | · | |
| Other Current Assets | · | · | · | · | · | · | · | · | $2M | $2M | $1M | $587.2K | |
| Current Assets | $38M | $37M | $29M | $35M | $35M | $69M | $37M | $47M | $49M | $79M | $85M | $95M | |
| PP&E (Net) | $5M | $6M | $6M | $2M | $2M | $3M | $2M | $3M | $3M | $1M | $2M | $1M | |
| PP&E (Gross) | $15M | $16M | $15M | $10M | $10M | $9M | $8M | $9M | $12M | $11M | $11M | $10M | |
| Accum. Depreciation | $11M | $10M | $9M | $8M | $7M | $7M | $6M | $6M | $9M | $10M | $9M | $9M | |
| Goodwill | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $920.7K | $920.7K | $920.7K | $920.7K | $920.7K | |
| Intangibles | $10M | $10M | $11M | $0 | · | · | · | · | $4.0K | $4.4K | $165.7K | $332.7K | |
| Other Non-current Assets | $556.0K | $528.0K | $527.0K | $523.0K | $619.0K | $629.0K | $435.0K | $536.5K | $494.8K | $501.2K | $462.8K | $542.2K | |
| Total Assets | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Accounts Payable | $2M | $3M | $5M | $4M | $4M | $4M | $3M | $4M | $4M | $6M | $4M | $5M | |
| Accrued Liabilities | $4M | $6M | $7M | $8M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | |
| Current Liabilities | $10M | $14M | $17M | $18M | $21M | $13M | $12M | $13M | $9M | $10M | $8M | $10M | |
| Capital Leases | $1M | $2M | $1M | $3M | · | $2M | $2M | · | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $14.0K | $14.0K | $14.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $20M | $27M | $31M | $33M | $46M | $44M | $24M | $25M | $26M | · | · | · | |
| Long-term Debt | $9M | · | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Total Debt | $9M | $8M | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Common Stock | · | · | · | · | · | · | · | · | · | $268M | $258M | $249M | |
| Paid-in Capital | $440M | $430M | $418M | $403M | $373M | $372M | $327M | $300M | · | · | · | · | |
| Retained Earnings | $-403M | $-398M | $-397M | $-389M | $-370M | $-337M | $-307M | $-272M | $-240M | $-214M | $-195M | $-180M | |
| AOCI | $131.0K | $54.0K | $-1.0K | $163.0K | $52.0K | $57.0K | $52.0K | $63.1K | $-35.4K | $-902.5K | $-915.5K | $-197.7K | |
| Stockholders' Equity | $37M | $33M | $21M | $14M | $3M | $34M | $20M | $27M | $33M | $53M | $62M | $69M | |
| Liabilities + Equity | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Shares Outstanding | 3,940,530 | 3,405,692 | 29,130,607 | 12,163,673 | 8,544,225 | 8,506,651 | 65,378,890 | 57,034,154 | 51,768,424 | 51,527,711 | 51,501,877 | 50,284,007 |
Cash Flow 16
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $1M | $576.0K | $668.0K | $834.0K | $788.0K | $650.1K | $514.4K | $762.4K | $822.3K | $996.3K | |
| Stock-based Comp | $2M | $1M | $932.0K | $315.0K | $943.0K | $475.0K | $5M | $4M | $7M | $10M | $9M | $10M | |
| Amort. of Intangibles | · | · | $300.0K | · | · | · | · | · | · | · | · | · | |
| Restructuring | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-966.0K | $-317.0K | $-11M | $-2M | $-7M | $-3M | $-887.5K | $3M | $-6M | $-8M | $-20M | $27M | |
| Operating Cash Flow | $-659.0K | $4M | $-9M | $-17M | $-34M | $-30M | $-27M | $-20M | $-21M | $-12M | $-13M | $4M | |
| CapEx | $542.0K | $1M | $284.0K | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $-9M | $-5M | $-3M | $-2M | $311.0K | $3M | $-5M | $13M | $15M | $-2M | $-21M | $-9M | |
| Debt Issued | · | · | · | · | $0 | $22M | $0 | · | · | · | · | · | |
| Net Debt Issued | · | · | · | · | $0 | $22M | · | · | · | · | · | · | |
| Stock Issued | $8M | $10M | $15M | $15M | · | · | $5M | $22M | $123.6K | · | · | · | |
| Net Stock Activity | $8M | $10M | $15M | · | · | · | · | $22M | · | · | · | · | |
| Financing Cash Flow | $4M | $7M | $11M | $16M | $-2M | $63M | $21M | $22M | $-2M | $80.2K | $-132.7K | $58M | |
| Net Change in Cash | $-5M | $7M | $-1M | $-3M | $-35M | $37M | $-11M | $14M | $-9M | $-14M | $-35M | $54M | |
| Taxes Paid | $0 | · | · | · | · | · | · | · | · | $404.5K | · | · | |
| Free Cash Flow | $-1M | $3M | · | · | · | · | · | · | · | · | · | · |
Profitability 8
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% | 4.4% | 4.6% | -2.5% | 6.5% | 12.7% | 16.2% | 15.8% | |
| Operating Margin | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% | -45.7% | -56.3% | -51.2% | -45.2% | -37.9% | -27.3% | -32.4% | |
| Net Margin | -7.7% | -0.47% | -10.1% | -25.7% | -52.8% | -49.7% | -55.7% | -50.7% | -45.2% | -37.2% | -26.1% | -39.4% | |
| Pretax Margin | -7.7% | -0.47% | · | · | · | · | · | · | -45.2% | -36.4% | -26.1% | -39.4% | |
| EBITDA Margin | -3.6% | 2.8% | -6.2% | -22.3% | -47.9% | -44.4% | -55.0% | -50.1% | -44.3% | -36.5% | -25.8% | -30.6% | |
| ROA | -9.1% | -0.86% | -17.1% | -39.2% | -51.7% | -50.6% | -70.5% | -57.7% | -36.5% | -23.2% | -15.5% | -31.8% | |
| ROE | -15.8% | -1.6% | -39.4% | -123.5% | -479.5% | -81.0% | -155.1% | -160.8% | -60.4% | -34.4% | -22.0% | -61.6% | |
| ROIC | -10.2% | 1.5% | · | · | · | · | · | · | -78.8% | -39.0% | -24.2% | -25.6% |
Liquidity & Solvency 5
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 | 5.4 | 3.0 | 3.5 | 5.3 | 7.7 | 10.5 | 9.7 | |
| Quick Ratio | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 | 4.1 | 1.3 | 3.1 | 4.3 | 6.3 | 9.4 | 9.2 | |
| Debt / Equity | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 | 0.6 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.2 | 0.3 | 0.4 | 0.5 | 5.2 | 0.6 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -2.9 | -8.7 | -12.9 | -15.1 | · | · | · | · | · | · |
Efficiency 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.2 | 1.8 | 1.7 | 1.5 | 1.0 | 1.0 | 1.3 | 1.1 | 0.8 | 0.6 | 0.6 | 0.8 | |
| Inventory Turnover | 12.5 | 14.4 | 12.8 | 13.9 | 16.1 | 15.7 | 15.2 | 11.1 | 5.4 | 4.7 | 7.9 | 13.6 | |
| Receivables Turnover | 8.4 | 10.6 | 9.7 | 12.0 | 12.3 | 14.9 | 11.0 | 9.5 | 9.0 | 9.3 | 11.6 | 12.0 |
Growth Rates 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -31.8% | 21.4% | 14.8% | 17.6% | -0.43% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -1.7% | 17.9% | 10.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.2% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 14
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Net Income TTM | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| Market Cap | $33M | $69M | $55M | $12M | $424M | $1.04B | $1.75B | $1.42B | $3.31B | $3.71B | $5.80B | $5.69B | |
| Enterprise Value | $31M | $62M | $54M | $11M | $431M | $1.01B | · | · | · | · | · | · | |
| P/E | -5.5 | -68.0 | -5.1 | -0.8 | -1.2 | -27.1 | -58.3 | -54.0 | -125.5 | -184.7 | -388.4 | -217.5 | |
| P/S | 0.5 | 0.7 | 0.7 | 0.2 | 6.8 | 16.7 | 28.6 | 22.4 | 57.8 | 69.7 | 104.8 | 104.9 | |
| P/B | 0.9 | 2.1 | 2.6 | 0.9 | 167.2 | 30.4 | 86.4 | 52.0 | 100.7 | 70.1 | 93.1 | 82.8 | |
| P / Tangible Book | 1.2 | 3.2 | 5.7 | 0.9 | 262.6 | 31.3 | · | · | · | · | · | · | |
| P / Cash Flow | -49.6 | 16.5 | -5.8 | -0.7 | -12.6 | -35.1 | -64.3 | -69.4 | -157.0 | -298.1 | -357.2 | 1335.5 | |
| P / FCF | -27.2 | 21.8 | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -12.3 | 22.3 | -10.4 | -0.7 | -14.5 | -36.7 | · | · | · | · | · | · | |
| EV / FCF | -25.7 | 19.5 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 0.4 | 0.6 | 0.7 | 0.2 | 7.0 | 16.3 | · | · | · | · | · | · | |
| Earnings Yield | -18.1% | -1.5% | -19.6% | -129.7% | -84.9% | -3.7% | -1.7% | -1.8% | -0.80% | -0.54% | -0.26% | -0.46% |
Income Statement 14
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18M | $17M | $18M | $16M | $16M | $19M | $25M | $28M | $26M | $23M | $22M | $24M | $18M | $20M | $19M | $19M | |
| Cost of Revenue | $15M | $14M | $14M | $14M | $14M | $16M | $21M | $22M | $21M | $20M | $19M | $22M | $17M | $17M | $17M | $18M | |
| Gross Profit | $3M | $3M | $4M | $2M | $3M | $3M | $4M | $6M | $5M | $3M | $3M | $2M | $1M | $3M | $2M | $777.0K | |
| R&D Expense | $40.0K | · | $0 | $0 | $0 | $0 | $1.0K | $0 | $0 | $18.0K | $168.0K | $494.0K | $167.0K | $278.0K | · | $469.0K | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | |
| Operating Income | $-1M | $-1M | $-398.0K | $-2M | $-1M | $-1M | $-519.0K | $2M | $515.0K | $-1M | $-547.0K | $-2M | $-3M | $-1M | $-2M | $-4M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $431.0K | · | $411.0K | $395.0K | $387.0K | $435.0K | $476.0K | |
| Other Non-op | $-111.0K | $-125.0K | $-156.0K | $-169.0K | $-143.0K | $-155.0K | $-237.0K | $-272.0K | $-172.0K | $-407.0K | $-965.0K | $-135.0K | $-346.0K | $-323.0K | $-396.0K | $-482.0K | |
| Net Income | $-1M | $-2M | $-554.0K | $-2M | $-1M | $-2M | $-756.0K | $2M | $343.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $-2M | $-4M | |
| EPS (Basic) | $-0.34 | $-0.04 | $-0.01 | $-0.05 | $-0.48 | $-0.04 | $-0.03 | $0.05 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| EPS (Diluted) | $-0.70 | $-0.04 | $-0.01 | $-0.05 | $-0.05 | $-0.04 | $-0.02 | $0.04 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| Shares (Basic) | 3,958,568 | 39,418,302 | -68,469,655 | 36,024,940 | 3,431,130 | 34,107,640 | -60,272,092 | 31,551,805 | 30,451,622 | 29,327,204 | -41,054,753 | 27,521,088 | 18,496,640 | 18,359,940 | -24,295,154 | 18,463,673 | |
| Shares (Diluted) | 3,958,568 | 39,418,302 | -68,469,655 | 36,024,940 | 3,431,130 | 34,107,640 | -62,722,609 | 32,420,168 | 32,033,776 | 29,327,204 | -41,054,753 | 27,521,088 | 18,496,640 | 18,359,940 | -24,295,154 | 18,463,673 | |
| EBITDA | $-1M | $-969.0K | · | $-2M | $-1M | $-821.0K | · | $2M | $515.0K | $-779.0K | · | $-2M | $-3M | $-1M | · | $-4M |
Balance Sheet 26
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $10M | $11M | $14M | $12M | $11M | $16M | $12M | $12M | $7M | $9M | $8M | $9M | $11M | $10M | $13M | |
| Receivables | $8M | $9M | $8M | $8M | $8M | $10M | $8M | $9M | $11M | $11M | $11M | $9M | $5M | $6M | $6M | $7M | |
| Inventory | $3M | $3M | $3M | $4M | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | $5M | |
| Prepaid Expense | $441.0K | $1M | $2M | $2M | $943.0K | $988.0K | $1M | $1M | $1M | $910.0K | $1M | $2M | $1M | $1M | $2M | $2M | |
| Current Assets | $36M | $37M | $38M | $38M | $32M | $33M | $37M | $34M | $30M | $27M | $29M | $28M | $28M | $30M | $35M | $42M | |
| PP&E (Net) | $5M | $4M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $7M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $14M | $14M | $15M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $15M | $15M | $10M | $10M | $10M | $10M | |
| Accum. Depreciation | $9M | $10M | $11M | $12M | $11M | $11M | $10M | $10M | $10M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | |
| Goodwill | $920.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | |
| Intangibles | $9M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $11M | $11M | $11M | · | · | $0 | · | |
| Other Non-current Assets | $556.0K | $556.0K | $556.0K | $561.0K | $561.0K | $521.0K | $528.0K | $548.0K | $548.0K | $527.0K | $527.0K | $527.0K | $527.0K | $522.0K | $523.0K | $522.0K | |
| Total Assets | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Accounts Payable | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $5M | $5M | $4M | $6M | $5M | $4M | $3M | |
| Accrued Liabilities | $4M | $3M | $4M | $4M | $4M | $5M | $6M | $6M | $6M | $5M | $7M | $7M | $4M | $4M | $8M | $6M | |
| Current Liabilities | $11M | $10M | $10M | $10M | $11M | $11M | $14M | $14M | $15M | $15M | $17M | $21M | $17M | $15M | $18M | $19M | |
| Capital Leases | $3M | $3M | $1M | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $1M | $2M | $2M | $2M | $3M | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Total Liabilities | $21M | $22M | $20M | $20M | $22M | $22M | $27M | $28M | $30M | $30M | $31M | $31M | $29M | $28M | $33M | $38M | |
| Long-term Debt | $9M | $9M | · | · | · | · | · | · | · | · | · | $9M | $9M | $9M | $9M | $14M | |
| Total Debt | $9M | $9M | · | $9M | $9M | $9M | · | $8M | $8M | $8M | · | $9M | $9M | $9M | · | $14M | |
| Paid-in Capital | $441M | $440M | $440M | $439M | $431M | $431M | $430M | $426M | $422M | $420M | $418M | $417M | $403M | $403M | $403M | $402M | |
| Retained Earnings | $-406M | $-405M | $-403M | $-402M | $-401M | $-399M | $-398M | $-397M | $-399M | $-399M | $-397M | $-396M | $-394M | $-391M | $-389M | $-386M | |
| AOCI | $130.0K | $133.0K | $131.0K | $73.0K | $57.0K | $60.0K | $54.0K | $8.0K | $-5.0K | $24.0K | $-1.0K | $68.0K | $137.0K | $156.0K | $163.0K | $54.0K | |
| Stockholders' Equity | $35M | $36M | $37M | $37M | $30M | $32M | $33M | $29M | $23M | $21M | $21M | $22M | $10M | $13M | $14M | $16M | |
| Liabilities + Equity | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Shares Outstanding | 3,972,029 | 39,470,299 | 39,405,302 | 39,405,301 | 34,430,352 | 34,257,903 | 34,056,920 | 32,318,806 | 31,030,218 | 29,556,474 | 29,130,607 | 28,489,663 | 16,795,673 | 12,552,673 | 12,163,673 | 11,152,673 |
Cash Flow 13
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $492.0K | $511.0K | $546.0K | $544.0K | $563.0K | $539.0K | $543.0K | $543.0K | $549.0K | $545.0K | $550.0K | $564.0K | $170.0K | $160.0K | $154.0K | $143.0K | |
| Stock-based Comp | $403.0K | $479.0K | $457.0K | $532.0K | $382.0K | $445.0K | $382.0K | $321.0K | $338.0K | $251.0K | $218.0K | $212.0K | $309.0K | $193.0K | $220.0K | $177.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | $100.0K | · | · | · | · | |
| Restructuring | · | · | $200.0K | $500.0K | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $448.0K | · | · | · | $-3M | · | · | · | $-1M | · | · | · | $-6M | · | · | |
| Operating Cash Flow | $2M | $-167.0K | $2M | $-1M | $2M | $-3M | $865.0K | $4M | $1M | $-2M | $-43.0K | $-4M | $-2M | $-4M | $-112.0K | $-1M | |
| CapEx | $617.0K | $425.0K | $86.0K | $229.0K | $164.0K | $63.0K | $395.0K | $191.0K | $286.0K | $139.0K | $43.0K | · | · | · | · | · | |
| Investing Cash Flow | $-487.0K | $-122.0K | $-4M | $-4M | $-103.0K | $-1.0K | $-332.0K | $-6M | $2M | $-139.0K | $2M | $-10M | $-64.0K | $5M | $3M | $-15M | |
| Stock Issued | · | · | $0 | $8M | $0 | $0 | $4M | $4M | $2M | $560.0K | $1M | $14M | $0 | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $560.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $-683.0K | $-813.0K | $-1M | $7M | $-650.0K | $-783.0K | $3M | $2M | $2M | $178.0K | $-742.0K | $13M | $-130.0K | $-631.0K | $-6M | $-2M | |
| Net Change in Cash | $910.0K | $-1M | $-3M | $1M | $1M | $-4M | $3M | $475.0K | $5M | $-2M | $1M | $-1M | $-2M | $792.0K | $-3M | $-18M | |
| Free Cash Flow | · | $-592.0K | · | · | · | $-4M | · | · | · | · | · | · | · | · | · | · |
Profitability 6
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.2% | 16.7% | · | 14.3% | 15.6% | 16.1% | · | 22.0% | 17.6% | 13.5% | · | 9.3% | 5.7% | 13.2% | · | 4.2% | |
| Operating Margin | -6.0% | -8.5% | · | -10.0% | -8.4% | -7.2% | · | 6.8% | 2.0% | -5.8% | · | -7.3% | -16.4% | -7.3% | · | -19.8% | |
| Net Margin | -6.6% | -9.3% | · | -11.0% | -9.3% | -8.0% | · | 5.9% | 1.3% | -7.6% | · | -7.9% | -18.3% | -8.9% | · | -22.4% | |
| EBITDA Margin | -6.0% | -5.6% | · | -10.0% | -8.4% | -4.3% | · | 6.8% | 2.0% | -3.4% | · | -7.3% | -16.4% | -6.4% | · | -19.8% | |
| ROA | -2.1% | -2.9% | · | -3.1% | -2.8% | -2.9% | · | 3.0% | 0.75% | -3.8% | · | -3.5% | -6.8% | -4.5% | · | -7.4% | |
| ROE | -3.6% | -4.8% | · | -5.3% | -5.5% | -5.8% | · | 6.6% | 2.1% | -10.4% | · | -9.9% | -22.3% | -45.2% | · | -30.8% |
Liquidity & Solvency 5
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.7 | · | 3.9 | 2.9 | 2.9 | · | 2.4 | 2.0 | 1.8 | · | 1.3 | 1.6 | 2.0 | · | 2.2 | |
| Quick Ratio | 1.7 | 1.9 | · | 2.3 | 1.9 | 1.9 | · | 1.5 | 1.5 | 1.2 | · | 0.8 | 0.8 | 1.1 | · | 1.1 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.4 | 1.0 | 0.7 | · | 0.9 | |
| LT Debt / Equity | 0.2 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.2 | 0.5 | 0.5 | · | 0.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -3.1 | · | -4.2 | -7.5 | -3.7 | · | -7.8 |
Efficiency 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.4 | · | 0.5 | 0.6 | 0.5 | · | 0.4 | 0.4 | 0.5 | · | 0.3 | |
| Inventory Turnover | 4.2 | 3.6 | · | 2.8 | 2.7 | 2.9 | · | 3.9 | 3.6 | 3.4 | · | 4.1 | 3.1 | 3.1 | · | 4.0 | |
| Receivables Turnover | 2.2 | 1.9 | · | 1.9 | 1.7 | 1.8 | · | 3.1 | 3.2 | 2.6 | · | 2.8 | 2.7 | 3.0 | · | 2.8 |
Valuation (TTM) 14
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $67M | $68M | · | $79M | $89M | $96M | · | $101M | $90M | $84M | · | $80M | $75M | $73M | · | $69M | |
| Net Income TTM | $-6M | $-6M | · | $-3M | $-1M | $-1M | · | $-2M | $-7M | $-9M | · | $-11M | $-14M | $-18M | · | $-24M | |
| Market Cap | $22M | $35M | · | $47M | $29M | $39M | · | $128M | $55M | $49M | · | $59M | $92M | $23M | · | $15M | |
| Enterprise Value | $20M | $34M | · | $42M | $25M | $36M | · | $124M | $51M | $51M | · | $60M | $92M | $21M | · | $16M | |
| P/E | -30.6 | -4.9 | · | -12.0 | -21.2 | -22.6 | · | -49.6 | -5.9 | -4.0 | · | -3.6 | -5.8 | -1.1 | · | -0.6 | |
| P/S | 0.3 | 0.5 | · | 0.6 | 0.3 | 0.4 | · | 1.3 | 0.6 | 0.6 | · | 0.7 | 1.2 | 0.3 | · | 0.2 | |
| P/B | 0.6 | 1.0 | · | 1.3 | 1.0 | 1.2 | · | 4.4 | 2.3 | 2.4 | · | 2.8 | 9.6 | 1.8 | · | 0.9 | |
| P / Tangible Book | 0.9 | 1.4 | · | 1.8 | 1.5 | 1.9 | · | 7.2 | 4.5 | 5.4 | · | 6.1 | 10.7 | 2.0 | · | 1.0 | |
| P / Cash Flow | · | -210.4 | · | · | · | -11.1 | · | · | · | -20.6 | · | · | · | -5.9 | · | · | |
| P / FCF | · | -59.3 | · | · | · | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -19.2 | -35.5 | · | -26.8 | -18.9 | -43.7 | · | 64.2 | 99.1 | -65.1 | · | -34.8 | -31.1 | -16.7 | · | -4.3 | |
| EV / FCF | · | -58.2 | · | · | · | -10.1 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 0.3 | 0.5 | · | 0.5 | 0.3 | 0.4 | · | 1.2 | 0.6 | 0.6 | · | 0.8 | 1.2 | 0.3 | · | 0.2 | |
| Earnings Yield | -3.3% | -20.2% | · | -8.3% | -4.7% | -4.4% | · | -2.0% | -17.1% | -24.7% | · | -27.9% | -17.2% | -88.4% | · | -181.1% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $69M | $101M | $84M | $73M | $62M |
| Gross Margin % | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% |
| Operating Margin % | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% |
| Net Income | $-5M | $-480.0K | $-8M | $-19M | $-33M |
| Diluted EPS | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debt / Equity | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 |
| Current Ratio | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 |
| Quick Ratio | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 |
Cash Flow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Free Cash Flow | $-1M | $3M | — | — | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 37 filers · $2.7M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 9 (-2 vs prior Q) | 14 (+9 vs prior Q) | 6 (-2 vs prior Q) | 9 (0 vs prior Q) | +1.0M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $986,089 | 1,182,361 | 36.75% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $677,668 | 1,229,888 | 25.26% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $197,999 | 359,672 | 7.38% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $169,240 | 288,030 | 6.31% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $128,196 | 232,660 | 4.78% | Shares |
| Wealthspire Advisors, LLC | $83,587 | 151,838 | 3.12% | Shares |
| JANE STREET GROUP, LLC | $81,822 | 148,633 | 3.05% | Shares |
| BlackRock, Inc. | $79,688 | 144,756 | 2.97% | Shares |
| STATE STREET CORP | $55,548 | 100,904 | 2.07% | Shares |
| NORTHERN TRUST CORP | $50,570 | 91,862 | 1.88% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $38,179 | 69,353 | 1.42% | Shares |
| CORSAIR CAPITAL MANAGEMENT, L.P. | $27,525 | 50,000 | 1.03% | Shares |
| LPL Financial LLC | $22,163 | 40,259 | 0.83% | Shares |
| WealthTrust Axiom LLC | $18,166 | 33,000 | 0.68% | Shares |
| Spartan Wealth Advisory Services LLC | $13,768 | 25,010 | 0.51% | Shares |
| TWO SIGMA SECURITIES, LLC | $13,621 | 24,743 | 0.51% | Shares |
| Tower Research Capital LLC (TRC) | $7,919 | 14,386 | 0.30% | Shares |
| Burford Brothers, Inc. | $7,799 | 14,168 | 0.29% | Shares |
| XTX Topco Ltd | $6,157 | 11,184 | 0.23% | Shares |
| Vanguard Global Advisers, LLC | $5,825 | 10,571 | 0.22% | Shares |
| Savvy Advisors, Inc. | $5,505 | 10,000 | 0.21% | Shares |
| WELLS FARGO & COMPANY/MN | $2,753 | 5,000 | 0.10% | Shares |
| MORGAN STANLEY | $1,091 | 1,982 | 0.04% | Shares |
| SHP Wealth Management | $782 | 1,421 | 0.03% | Shares |
| IFG Advisory, LLC | $369 | 670 | 0.01% | Shares |
| GROUP ONE TRADING LLC | $255 | 463 | 0.01% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $168 | 258 | 0.01% | Shares |
| OSAIC HOLDINGS, INC. | $150 | 274 | 0.01% | Shares |
| COMERICA BANK | $136 | 163 | 0.01% | Shares |
| BARCLAYS PLC | $115 | 209 | 0.00% | Shares |
| UBS Group AG | $110 | 200 | 0.00% | Shares |
| FIFTH THIRD BANCORP | $90 | 163 | 0.00% | Shares |
| GSA CAPITAL PARTNERS LLP | $38 | 69,800 | 0.00% | Shares |
| Farther Finance Advisors, LLC | $21 | 39 | 0.00% | Shares |
| Leo H. Evart, Inc. | $8 | 9 | 0.00% | Shares |
| Richmond Brothers, Inc. | $3 | 6 | 0.00% | Shares |
| FMR LLC | $3 | 6 | 0.00% | Shares |
Company insiders 33 insiders · 17 officers · 18 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Mark Strobeck | President and CEO | July 1, 2026 A | 62,349 | 0 | 0 | $0 |
| Stuart M Paul | Chief Executive Officer | Sept. 4, 2019 F | 330,056 | 0 | 0 | $0 |
| CHIOINI ROBERT L | Chairman, President and CEO | Dec. 15, 2017 M | 2,549,907 | 0 | 0 | $0 |
| Jesse Neri | SVP and CFO | July 1, 2026 A | 27,239 | 0 | 0 | $0 |
| Russell Skibsted | EVP, Chief Financial Officer and Chief Business Officer | Sept. 9, 2022 A | — | 0 | 0 | $0 |
| Angus W. Smith | Chief Financial Officer | Nov. 28, 2019 F | 168,486 | 0 | 0 | $0 |
| Thomas E Klema | Vice President, CFO | Dec. 15, 2017 M | 671,492 | 0 | 0 | $0 |
| Heather Hunter | Chief Operating Officer | July 1, 2026 A | 28,007 | 0 | 1 | $-3,413 |
| Megan C. Timmins | EVP, CLO & Secretary | July 1, 2026 A | 31,240 | 0 | 0 | $0 |
| Timothy Chole | SVP, Chief Commercial Officer | May 20, 2025 A | 131,035 | 0 | 0 | $0 |
| Marc L Hoffman | Chief Medical Officer | March 17, 2023 A | 25,665 | 0 | 0 | $0 |
| Paul E Mcgarry | SVP, Finance and CAO | March 17, 2023 A | 28,515 | 0 | 0 | $0 |
| Ajay Gupta | Sr. VP & Chief Scientific Off. | Oct. 7, 2019 F | 576,458 | 0 | 0 | $0 |
| David Kull | Principal Accounting Officer | April 25, 2019 A | 13,270 | 0 | 0 | $0 |
| Raymond Dennis Pratt | Chief Medical Officer | April 25, 2019 A | 357,970 | 0 | 0 | $0 |
| Annamaria T Kausz | VP of Drug Development | Sept. 23, 2011 A | — | 0 | 0 | $0 |
| Richard C Yocum | VP - Clin. Dev. & Med. Affairs | Jan. 15, 2010 A | — | 0 | 0 | $0 |
| Joseph H Dawson | Director | July 1, 2026 A | 12,133 | 0 | 0 | $0 |
| Joan Lau | Director | July 1, 2026 A | 20,944 | 0 | 0 | $0 |
| Robert S Radie | Director | July 1, 2026 A | 23,985 | 0 | 0 | $0 |
| Allen Nissenson | Director | July 1, 2026 A | 23,892 | 0 | 0 | $0 |
| John G Cooper | Director | July 1, 2026 A | 23,670 | 0 | 0 | $0 |
| Andrea Heslin Smiley | Director | May 20, 2025 A | 142,062 | 0 | 0 | $0 |
| Mark H Ravich | Director | May 20, 2025 A | 148,831 | 0 | 0 | $0 |
| John Peter Mclaughlin | Director | Jan. 29, 2020 A | 35,174 | 0 | 0 | $0 |
| Russell H Ellison | Director | Jan. 9, 2020 A | 10,050 | 0 | 0 | $0 |
| Benjamin Wolin | Director | June 6, 2019 A | 27,710 | 0 | 0 | $0 |
| Robin L Smith | Director | June 6, 2019 A | 31,366 | 0 | 0 | $0 |
| Lisa N Colleran | Director | June 6, 2019 A | 18,674 | 0 | 0 | $0 |
| Patrick J Bagley | Director | March 19, 2018 A | 116,307 | 0 | 0 | $0 |
| Ronald D Boyd | Director | March 19, 2018 A | 42,678 | 0 | 0 | $0 |
| Kenneth L Holt | Director | March 16, 2017 S | 12,630 | 0 | 0 | $0 |
| HAGELSTEIN DAVID A | 10% owner | Jan. 28, 2013 J | 1,360,700 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 15 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Richmond Brothers, Inc., RBI Private Investment I, LLC, RBI Private Investment II, LLC, The RBI Opportunities Fund, LLC, The RBI Opportunities Fund II, LLC, RBI PI Manager, LLC, Richmond Brothers 401(k) Profit Sharing Plan, David S. Richmond, Matthew J. Curfman ×18 filings | Sept. 6, 2023 | — | Initial filing | — | SEC |
| Robert L. Chioini ×10 filings | Dec. 29, 2017 | — | Initial filing | — | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, as amended, David A. Hagelstein | Aug. 13, 2013 | — | Initial filing | — | SEC |
| Thomas E. Klema ×3 filings | July 1, 2013 | — | Initial filing | — | SEC |
| Thomas E. Klema (2) | March 23, 2012 | — | Initial filing | — | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, David A. Hagelstein | Dec. 8, 2011 | — | Initial filing | — | SEC |
| David Hagelstein Charitable Remainder Unitrust Agreement, dated November 20, 2003, David A. Hagelstein, individually and the David A. Hagelstein Revocable Living Trust, dated October 27, 1993 ×4 filings | March 31, 2011 | — | Initial filing | — | SEC |
| Undisclosed reporting person | Feb. 13, 2007 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Feb. 13, 2007 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Feb. 6, 2006 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Dec. 27, 2005 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Dec. 27, 2005 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | July 18, 2005 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | April 22, 2005 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Jan. 23, 2004 | — | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 2 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.